Immunomodulatory drug costimulates T cells via the B7-CD28 pathway.

Although thalidomide (Thal) does not directly induce T-cell activation, it increases proliferation of T cells following CD3 activation. In this study, we examined the immunomodulatory effects of a more potent analog of Thal, immunomodulatory drug (IMiD), on T cells. Although IMiD3 does not directly stimulate proliferation of normal donor CD3+ T cells, it significantly costimulates proliferation of CD3+ T cells induced by CD3 ligation (stimulation index [SI], 2.4), immature dendritic cells (DCs; SI, 2.1), and mature DCs (SI, 2.6). T-cell proliferation triggered by DCs was abrogated by cytotoxic T lymphocyte antigen 4-immunoglobulin (CTLA-4-Ig), and IMiD3 partially overcomes this inhibitory effect. IMiD3 also overcomes the inhibitory effects of CTLA-4-Ig on Epstein-Barr virus (EBV) and influenza (Flu)-specific CD4 and CD8 T-cell responses, as measured by cytokine capture and enzyme-linked immunosorbent spot (ELISPOT) assay. IMiD3 did not induce up-regulation of CD28 expression on T cells, or of CD80-CD86 expression on dendritic cells. Importantly, IMiD3 triggers tyrosine phosphorylation of CD28 on T cells, followed by activation of nuclear factor kappaB (NF-kappaB), a known downstream target of CD28 signaling. These results therefore define the costimulatory mechanism whereby IMiD3 induces T-cell activation and provide the cellular and molecular basis for use of IMiD3 as an adjuvant in immunotherapeutic treatment strategies for multiple myeloma.

[1]  Adeeba Kamarulzaman,et al.  AIDS Res Hum Retroviruses , 2006 .

[2]  Richard LeBlanc,et al.  Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. , 2002, Blood.

[3]  N. Munshi,et al.  Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. , 2002, Blood.

[4]  A. Dalgleish,et al.  Protective Antitumor Immunity Induced by a Costimulatory Thalidomide Analog in Conjunction with Whole Tumor Cell Vaccination Is Mediated by Increased Th1-Type Immunity1 , 2002, The Journal of Immunology.

[5]  N. Munshi,et al.  NF-κB as a Therapeutic Target in Multiple Myeloma* , 2002, The Journal of Biological Chemistry.

[6]  A. Wettstein,et al.  Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease , 2002, Journal of gastroenterology and hepatology.

[7]  J. Kari,et al.  Behçet's disease in UK children: clinical features and treatment including thalidomide. , 2001, Rheumatology.

[8]  G. Morgan,et al.  Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. , 2001, Blood.

[9]  G Muller,et al.  Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. , 2000, Blood.

[10]  A. Fleischer,et al.  Thalidomide: current and potential clinical applications. , 2000, The American journal of medicine.

[11]  T. Elbeik,et al.  Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients. , 1999, AIDS research and human retroviruses.

[12]  P. Haslett,et al.  Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. , 1999, Journal of immunology.

[13]  P. Haslett,et al.  Thalidomide Costimulates Primary Human T Lymphocytes, Preferentially Inducing Proliferation, Cytokine Production, and Cytotoxic Responses in the CD8+ Subset , 1998, The Journal of experimental medicine.

[14]  G. Trinchieri,et al.  Inhibition of IL-12 production by thalidomide. , 1997, Journal of immunology.

[15]  A. Kumar,et al.  Immediate Early and Early Lytic Cycle Proteins Are Frequent Targets of the Epstein-Barr Virus–induced Cytotoxic T Cell Response , 1997, The Journal of experimental medicine.

[16]  C. Rudd,et al.  p56Lck and p59Fyn regulate CD28 binding to phosphatidylinositol 3-kinase, growth factor receptor-bound protein GRB-2, and T cell-specific protein-tyrosine kinase ITK: implications for T-cell costimulation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[17]  G. Kaplan,et al.  The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. , 1993, The Journal of infectious diseases.

[18]  H. Inoko,et al.  Target epitope in the Tax protein of human T-cell leukemia virus type I recognized by class I major histocompatibility complex-restricted cytotoxic T cells , 1992, Journal of virology.

[19]  D. Jabs,et al.  Thalidomide for the treatment of chronic graft-versus-host disease. , 1992, The New England journal of medicine.

[20]  J. Allison,et al.  CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones , 1992, Nature.

[21]  G. Kaplan,et al.  Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes , 1991, The Journal of experimental medicine.

[22]  G. Crabtree,et al.  Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28. , 1991, Science.

[23]  R. Schwartz,et al.  An accessory cell-derived costimulatory signal acts independently of protein kinase C activation to allow T cell proliferation and prevent the induction of unresponsiveness. , 1989, Journal of immunology.

[24]  A. McMichael,et al.  Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2 , 1987, Nature.

[25]  Melvin Cohn,et al.  A Theory of Self-Nonself Discrimination , 1970, Science.

[26]  T. Hideshima,et al.  Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo , 2003, Leukemia.

[27]  N. Munshi,et al.  NF-kappa B as a therapeutic target in multiple myeloma. , 2002, The Journal of biological chemistry.

[28]  M. Raab.  p56^ and p59^ regulate CD28 binding to phosphatidylinositol 3-kinase, growth factor receptor binding protein GRB-2 and T cell specific kinase ITK: implications for T cell co-stimulation. , 1995 .